AARD Projected Dividend Yield
Aardvark Therapeutics Inc ( NASDAQ : AARD )Aardvark Therapeutics is a clinical-stage biopharmaceutical focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic diseases. Co. focused on developing Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Co. lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs for which Co. initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). 21 YEAR PERFORMANCE RESULTS |
AARD Dividend History Detail AARD Dividend News AARD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |